Écrit par GlobalData | 22 Février 2018

The ‘Made in China 2025’ ten-year national plan, which is aimed at propelling explosive growth in the biomedical and high-end medical device manufacturing industry, will increase competition in the Chinese medical device market, according to leading data and analytics company, GlobalData.

China has earmarked the biomedical and high-end medical device manufacturing industry as one of...

Écrit par NEOVACS | 22 Février 2018

Ce brevet porte sur l'IFNα Kinoïde et son utilisation dans les maladies liées à la surproduction de la cytokine IFNα



Paris et Boston, le 22 Février 2018 - 07 :00 CET - Néovacs (Euronext Growth Paris :  ALNEV), leader de l'immunothérapie active pour le traitement des maladies auto-immunes annonce aujourd'hui avoir reçu la notification par le United States Patent and Trademark...

Écrit par Didier Poli | 21 Février 2018

Orthotaxy’s Technology Will Be Leveraged to Develop Cost-Effective, Time-Efficient,  User-Friendly Offering in a Broad Range of Orthopaedics Procedures

PARIS – February 20, 2018 – Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced today the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery technologies...

Écrit par GlobalData | 21 Février 2018

The list of failed Alzheimer’s drugs continued to grow in 2017, as another two names were added to the list of drugs that failed to hit the mark in Phase III clinical trials. Both Axovant’s intepiridine and Lundbeck’s idalopirdine failed their Phase III clinical trials, leaving the Alzheimer’s pipeline no closer to a FDA-approved breakthrough, observe GlobalData, a leading data and...